Navigation Links
Cell Therapeutics Closes Italian Facility, Reduces Headcount and Expects to Cut $14 Million in Operating Expenses
Date:5/15/2009

>include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, CTI's ability to continue to raise capital as needed to fund its operation, CTI's reduction in annual operating expenses may be less than projected and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q, and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.282.7100
    Lindsey Jesch
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Selexis SA, a serial innovation company with proven ... for drug discovery to commercial manufacturing, announced today all ... Sequencing (NGS) data packages. The NGS analysis of ... the integrity of the gene, validation of the left ...
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision medicine ... to enable the broad use of genomic, imaging and other ... appointment of Michelle Munson , CEO of Aspera, an ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 "We ...
(Date:12/24/2014)... Texas , Dec. 24, 2014  Vermillion, Inc. ... on gynecologic disease, announced today that the Company ... including Oracle Investment Management, Jack W. Schuler ... Total proceeds were $10.5 million, before offering expenses.  ...
(Date:12/24/2014)... SoundConnect’s 2015 next ... edge communication technology, provide continued education and inform ... series demonstrates online communication features and benefits; empowering ... most innovative and powerful tools. , According to ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
... Biopharmaceuticals Ltd. (Nasdaq: XTLB , TASE: XTL) today ... regarding the Company,s activities in seeking to acquire potential assets ... XTL. The Company is currently evaluating several merger proposals that ... companies who operate in and outside of the healthcare space. ...
... 23andMe , Inc., an industry leader in ... research company dedicated to the development of treatments for ... in Davos, Switzerland, that they are collaborating to advance ... of the companies to the World Economic Forum, where ...
... dots created by researchers at Canada,s National Institute for ... new level of control over individual electrons, a development ... Composed of a single atom of silicon and measuring ... smallest quantum dots ever created. , Quantum ...
Cached Biology Technology:XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives 223andMe and mondoBIOTECH Partner to Advance Research of Rare Diseases 223andMe and mondoBIOTECH Partner to Advance Research of Rare Diseases 3Smallest ever quantum dots bring real world applications closer 2
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... addition of the "The Global Watermarking and ... http://photos.prnewswire.com/prnh/20130307/600769 ... digital media watermarking and fingerprinting markets. Watermarking aims ...
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, today announced ... genetic ancestry of individuals from across the United ... than four hundred years ago, the United States ... from different continents. This study illuminates how American history and ...
(Date:12/17/2014)...  HITLAB SM announced today its completion of a ... to current U.S. Food and Drug Administration (FDA) regulations. ... and smart phone application trials utilizing the highest principles ... is determined to improve global healthcare access, quality, and ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... by the Biotechnology and Biological Sciences Research Council and ... have developed a revolutionary way of capturing a high-resolution ... technology that is attractive for science, industry and consumer ... in standard cameras and digital movie projectors they have ...
... Feb. 12, 2010 -- By taking advantage of a ... for electronics designers, a team led by Oak Ridge ... biological sensor with unprecedented sensitivity. Ultimately, researchers believe ... approaches the theoretical limit, surpassing other state-of-the-art chemical sensors. ...
... Haven, Conn.Yale University scientists have streamlined the process for synthesizing ... and other diseased cells, and have found that they represent ... this week,s online edition of the Journal of the ... family of compounds known as the kinamycins, which are naturally ...
Cached Biology News:Cameras of the future: heart researchers create revolutionary photographic technique 2Cameras of the future: heart researchers create revolutionary photographic technique 3Cameras of the future: heart researchers create revolutionary photographic technique 4New ORNL sensor exploits traditional weakness of nano devices 2Scientists synthesize unique family of anti-cancer compounds 2
CHIMAERIC HUMAN IgA2 ANTI NP...
ANTI NO-TRYPTOPHAN CONJUGATE...
... The Captivate magnetic ... can be used in conjunction ... (C-21473, C-21474, C-21476) or other ... with most 96-well microplates. Cell ...
Protein Phosphorylation...
Biology Products: